Cancer treatment firm Sirtex Medical has completed enrollment in two Australian trials of its SIR-Spheres yttrium-90 resin microspheres for treating metastatic colorectal cancer.
The FOXFIRE and FOXFIRE Global trials are studying the overall survival benefit of adding Sirtex' first-line therapy to a chemotherapy regimen for inoperable metastatic colorectal cancer.
The trials are expected to answer whether the agent alone can significantly increase survival in this patient population. The results are expected in the first half of 2017.
FOXFIRE began in 2008 by the Oxford Oncology Clinical Trials Office in collaboration with the U.K. National Cancer Research Institute. Sponsored by the University of Oxford, it is funded by the Bobby Moore Fund for Cancer Research UK, the Experimental Cancer Medicine Centre Network, and Sirtex Medical.
